Kontafarma China Holdings Limited (1312.HK)
HKSE · HKD · Healthcare · Drug Manufacturers - Specialty & Generic
HK$0.03 (+0.00%) as of
Key statistics
- Market cap
- 167.66M
- EPS (TTM)
- -0.040
- Dividend yield
- 0.00%
- 52-week range
- 0.020 – 0.036
- Beta
- 0.03
- Revenue (TTM)
- 845.33M
- Profit margin
- -25.17%
- Volume
- 60.00k
About Kontafarma China Holdings Limited
Kontafarma China Holdings Limited, an investment holding company, manufactures and sells chemical drugs, active pharmaceutical ingredients (API), and API intermediates in Mainland China, Singapore, Taiwan, and internationally. The company operates through Pharmaceutical Business and Fitness Business segments. It provides prescription drugs, including chemical drugs and prescribed traditional Chinese medicines; operates fitness and yoga centers, as well as franchise business; and provides management and consultation services for fitness and health activities. The company also provides corporate advisory services; and researches and develops medical products. The company was formerly known as Tongfang Kontafarma Holdings Limited and changed its name to Kontafarma China Holdings Limited in September 2022. Kontafarma China Holdings Limited was incorporated in 2011 and is headquartered in Wan Chai, Hong Kong. Kontafarma China Holdings Limited is a subsidiary of Waranty Assets Management (Hk) Limited.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Wan Chai, Hong Kong
- Employees
- 625
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.